| Hazard Information | Back Directory | [Uses]
Laninamivir octanoate hydrate (CS-8958 hydrate), a prodrug of Laninamivir, is a long-acting neuraminidase (NA) inhibitor with anti-influenza virus activity. Laninamivir octanoate hydrate shows anti-influenza activity against Oseltamivir-resistant viruses, and also against the pandemic influenza viruses[1][2]. | [in vivo]
Laninamivir octanoate (CS-8958; 95 μg/kg; intranasal administration; three dose; at 4 h before and 4 h and 17 h postinfection) treatment shows significantly life-prolonging effect in infected model[1]. | Animal Model: | Female BALB/c mice (5-6 weeks old) infected with influenza A virus A/PR/8/34[1] | | Dosage: | 0.2 μmol/kg (95 μg/kg) | | Administration: | Intranasal administration; three dose; at 4 h before and 4 h and 17 h postinfection | | Result: | Showed life-prolonging effect in infected model. |
| [References]
[1] Makoto Yamashita, et al. CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. Antimicrob Agents Chemother. 2009 Jan;53(1):186-92. DOI:10.1128/AAC.00333-08
[2] Hideyuki Ikematsu, et al. Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza. Expert Rev Anti Infect Ther. 2011 Oct;9(10):851-7. DOI:10.1586/eri.11.112 |
|
|